Erasca Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
ERAS$15.48-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated statements of cash flows
Consolidated Statements of Cash Flows
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(125,042) | $(242,805) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 3,732 | 2,641 |
| Stock-based compensation expense | 26,231 | 20,109 |
| In-process research and development expenses | — | 102,000 |
| Accretion on marketable securities, net | (6,951) | (994) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current and long-term assets | 939 | (3,612) |
| Accounts payable | (886) | 676 |
| Accrued expenses and other current and long-term liabilities | (2,301) | 5,018 |
| Operating lease assets and liabilities, net | 3,061 | 13,703 |
| Net cash used in operating activities | (101,217) | (103,264) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (314,390) | (132,330) |
| Maturities of marketable securities | 244,945 | 79,800 |
| In-process research and development | (20,000) | (2,000) |
| Payment made for investment in equity securities | — | (2,000) |
| Purchases of property and equipment, net | (1,775) | (14,551) |
| Net cash used in investing activities | (91,220) | (71,081) |
| Cash flows from financing activities: | ||
| Proceeds from the issuance of common stock in underwritten offering, net of discounts and offering costs | — | 95,251 |
| Proceeds from the exercise of stock options | 505 | 2,004 |
| Proceeds from issuance of common stock under the Employee Stock Purchase Plan | 790 | 820 |
| Net cash provided by financing activities | 1,295 | 98,075 |
| Net decrease in cash, cash equivalents and restricted cash | (191,142) | (76,270) |
| Cash, cash equivalents and restricted cash at beginning of the period | 284,625 | 360,895 |
| Cash, cash equivalents and restricted cash at end of the period | $93,483 | $284,625 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Issuance of common stock in connection with license agreement | $— | $80,000 |
| Amounts accrued for in-process research and development | $— | $20,000 |
| Amounts accrued for purchases of property and equipment | $13 | $800 |
| Amounts accrued for offering costs | $— | $368 |
| Vesting of early exercised options | $1,231 | $1,193 |
| Operating lease assets obtained in exchange for lease obligation | $— | $22,704 |
| Reduction in operating lease assets due to lease amendment | $— | $3,361 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.